Big Board Alerts

Sandoz announces agreement to acquire CIMERLI business from Coherus, strengthening position in US market

Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. for an upfront cash purchase payment of USD 170 million. This is inclusive of a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.

Keren Haruvi, President Sandoz North America, said: “I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise. The addition of CIMERLI reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the US.”

Sandoz looks forward to providing even more treatment options for US patients with vision impairment and loss. The agreement to acquire the CIMERLI business from Coherus allows us to build a more robust ophthalmic platform that would support future product launches.

Closing is anticipated in 1H 2024, subject to standard conditions and approvals.

The post Sandoz announces agreement to acquire CIMERLI business from Coherus, strengthening position in US market appeared first on Pharma Journalist.

 

Latest Articles

DON’T MISS THE OPPORTUNITY TO JOIN OUR MARKET SUMMARY REPORT FOR A LIMITED TIME

By submitting this form on our website, you agree that we may collect and use your personal information for marketing, and for other purposes as set forth in our privacy policy, which we encourage you to review.